Quick Answer
aTYR PHARMA INC reported Research And Development Expense of $60.22 million for the year ending 2025.
- aTYR PHARMA INC showed an increase of +10.8% in Research And Development Expense from 2024 to 2025.
- This data is from aTYR PHARMA INC's annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), aTYR PHARMA INC's Research And Development Expense has grown by 335.4%.
- Historical annual values: Fiscal year 2025: $60.22 million | Fiscal year 2024: $54.37 million | Fiscal year 2023: $42.29 million | Fiscal year 2022: $42.81 million | Fiscal year 2021: $23.26 million | Fiscal year 2020: $17.29 million | Fiscal year 2019: $14.05 million | Fiscal year 2018: $20.39 million | Fiscal year 2017: $30.07 million | Fiscal year 2016: $42.85 million | Fiscal year 2015: $34.50 million | Fiscal year 2014: $16.78 million | Fiscal year 2013: $13.83 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: